Correction: Perillaldehyde reduces myocardial ischemia-reperfusion injury in rats by inhibiting MAPK1

In the originally published article [1], references [16, 17, 20, 21, 33] were found to be suboptimally related to the study topic or did not accurately reflect the viewpoint stated in the corresponding text.

These references have been replaced with more appropriate citations as follows:

[16] Yuan W, Shi Y, Dai S, Deng M, Zhu K, Xu YM, et al. The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects. Journal of Translational Medicine. 2024; 22: 1142.

[17] Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Experi-mental and Therapeutic Medicine. 2020; 19: 1997–2007.

[20] Młynarska E, Czarnik W, Fularski P, Hajdys J, Ma-jchrowicz G, Stabrawa M, et al. From atherosclerotic plaque to myocardial infarction-the leading cause of coronary artery occlusion. International Journal of Molecular Sciences. 2024; 25: 7295.

[21] Buja LM. Pathobiology of myocardial ischemia and reperfusion injury: models, modes, molecular mechanisms, modulation, and clinical applications. Cardiology in Review. 2023; 31: 252–264.

[33] Yuan Y, Huang H, Hu T, Zou CC, Qiao YM, Fang M, et al. Curcumin pretreatment attenuates myocardial is-chemia/reperfusion injury by inhibiting ferroptosis, autophagy and apoptosis via HES1. International Journal of Molecular Medicine. 2024; 54: 110.

The updated references have been inserted in the appropriate positions in the revised article. The authors confirm that these changes do not affect the scientific content, results, interpretations, or conclusions of the original study. The authors sincerely apologize for the oversight in the initial selection of these references.

[1] Chen W, Huang J, Li QK, Wu Q, Zhang CW, Yin R. Perillaldehyde reduces myocardial ischemia-reperfusion injury in rats by inhibiting MAPK1. Signa Vitae. 2024; 20: 97–105.